RA0125

antibody from Oursmab

Targeting: CD52 CDW52, EDDM5, HE5

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0125

Provider

Oursmab

Product name

Gatralimab (Biosimilar Reference Antibody) (CD52)

Antibody type

Monoclonal

Description

Gatralimab is a next-generation anti-CD52 monoclonal antibody (mAb) that was investigated for the treatment of progressive multiple sclerosis (MS). It belongs to the class of therapies aimed at immune cell depletion to modulate the pathogenic immune response in MS. Gatralimab functions by binding to the CD52 antigen on the surface of a broad range of immune cells, including T cells, B cells, and monocytes. Upon binding, it leads to the depletion of these target cells, primarily through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.